Arch Biopartners Inc. - ACHFF STOCK NEWS

Arch Biopartners Inc. announces the addition of Anesthesia Clinical Trials Unit (ACTU) at University Health Network to Phase II trial for LSALT peptide targeting cardiac surgery-associated acute kidney injury. The trial aims to evaluate the prevention and treatment of inflammation injury in kidneys, lungs, and liver.

Arch Biopartners Inc. expands Phase II trial for LSALT peptide with three new clinical sites in Turkey, targeting cardiac surgery-associated acute kidney injury.

Arch Biopartners Inc. publishes results of Phase II trial for LSALT peptide targeting acute lung and kidney inflammation in SARS-CoV-2 patients. The trial validates DPEP-1 as a therapeutic target and shows promising biomarker data supporting LSALT peptide's efficacy in reducing organ inflammation.

Arch Biopartners Inc. announced the addition of the University of Calgary's research team to the Phase II trial for LSALT peptide targeting cardiac surgery-associated acute kidney injury. The trial aims to prevent inflammation injury in kidneys, lungs, and liver, with a recruitment target of 240 patients. LSALT peptide targets the DPEP-1 pathway and has shown promise in pre-clinical models. The study is an international multi-center, double-blind, placebo-controlled trial.

Arch Biopartners Inc. initiates Phase II trial in Turkey for LSALT peptide targeting cardiac surgery-associated acute kidney injury, with a recruitment target of 240 patients. LSALT peptide aims to prevent inflammation injury in kidneys, lungs, and liver. The trial is a multi-center, double-blind study evaluating the percentage of subjects with AKI following on-pump cardiac surgery.

Arch Biopartners Inc. had a PIND meeting with the FDA to discuss repurposing cilastatin as a treatment for acute kidney injury, targeting toxin-related AKI. The company plans to sponsor a Phase II trial for cilastatin and has received guidance for an IND application. Arch is collaborating with clinical researchers for phase II studies in late 2024 and has method of use patents for repurposing cilastatin. The company aims to establish cilastatin as a new treatment for toxin-related AKI.

Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) receives No Objection Letter from Health Canada to conduct Phase II trial for LSALT peptide targeting prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The trial is an international multi-center, randomized, double-blind, placebo-controlled study. LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs, and liver. The Phase II trial aims to evaluate the percentage of subjects with AKI within 7 days following on-pump cardiac surgery. No therapeutic treatments are currently available for CS-AKI or ischemia-reperfusion injury (IRI). LSALT peptide targets the dipeptidase-1 (DPEP-1) pathway and has shown promising results in pre-clinical models. The Company has received prior approvals from the U.S. FDA and the Turkish Ministry of Health to proceed with the trial in their respective jurisdictions. The National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) will provide advisory services and a funding contribution for the trial.

Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The company's lead drug candidate, LSALT peptide, has shown promise in preventing ischemia-reperfusion injury (IRI) in pre-clinical models, providing a scientific rationale for its use in the CS-AKI trial. With patient enrollment planned to start in February 2024, Arch Biopartners Inc. is poised to make significant progress in addressing a common complication in patients after cardiac surgeries. The company has also received advisory services and a funding contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to offset the costs of the Phase II trial.

Arch Biopartners Inc. (TSX Venture: ARCH, OTCQB: ACHFF) receives approval in Turkey to proceed with Phase II trial for LSALT peptide targeting prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI)